Circulating tumor cells (CTCs) are promising surrogate markers for systemic disease, and their molecular characterization might be relevant to guide more individualized cancer therapies. To enable fast and efficient purification of individual CTCs, we developed a work flow from CellSearch TM cartridges enabling high-resolution genomic profiling on the singlecell level.
CONCLUSIONS:
This work flow enabled effective CTC isolation and provided insights into genomic alterations of CTCs in metastatic breast cancer. This approach might facilitate further molecular characterization of rare CTCs to increase understanding of their biology and as a basis for their molecular screening in the clinical setting.
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Circulating tumor cells (CTCs) 7 have recently gained much attention because they hold great promise as biomarkers for real-time monitoring of systemic cancer as a "liquid biopsy" for diagnosis and during therapy (1) (2) (3) (4) . Moreover, in light of the well-documented genetic and phenotypic differences between primary tumors and metastatic cells (5) (6) (7) (8) (9) , CTCs appear to be more suitable surrogate markers for systemic disease than the bulk tissue of the primary tumor. Currently, the accepted gold standard for CTC detection is the CellSearch TM system (Veridex LLC), which relies on immunomagnetic enrichment of cancer cells expressing the EpCAM (epithelial cell adhesion molecule) antigen that is normally absent on the membrane of hematopoietic cells (10 ) . Captured cells are then further qualified as CTCs on the basis of expression of cytokeratins (CK), nuclear counterstain with 4Ј,6-diamidino-2-phenylindole (DAPI), and absence of CD45 expression (11, 12 ) . A groundbreaking study using the CellSearch system in metastatic breast cancer showed that women with at least 5 CTCs per 7.5 mL of peripheral blood had a worse prognosis than those with fewer or no CTCs (12 ) . The clinical prognostic value of these cells illustrates the relevance of CTCs for tumor progression, which was further supported by their capacity to initiate metastasis in mouse xenograft assays (13 ) .
Because of the extreme rarity of the CTCs (4 ), their further analysis is technically challenging, and consequently not much is known about their molecular and genetic characteristics (14 ) . Comprehensive genetic characterization downstream of their immunological detection might help in the acquisition of a more complete picture of the biology of the CTC population and may facilitate a more personalized therapy, eventually targeting specific CTC subtypes. Therefore, it would be highly desirable to further analyze the captured cells. The release of these captured and stained cells from the diagnostic CellSearch cartridges is possible, although the kit was originally not designed for this. The very low concentration of CTCs and the unpredictable number of "contaminating" hematopoietic cells always cocaptured as background by the CellSearch system hamper direct downstream molecular analyses, and hence further purification and isolation of the rare CTCs is required. Initial data indicated that flow-sorting approaches might be suitable for CTC purification (15 ) , but efficient protocols have been lacking. Here, we present a protocol to efficiently purify single CTCs captured with the CellSearch circulating tumor cell kit that enables their further comprehensive genetic analysis on a single-cell level. The proposed protocol can be used for affordable and systematic isolation of CTCs from clinical CellSearch samples. As a downstream readout system, we used single-cell arraybased comparative genomic hybridization (aCGH) to screen the whole genome of single CTCs isolated from advanced metastatic breast cancer patients with Ն5 marker-positive CTCs for copy number alterations (CNAs) (16 ) . Tables 1-6 
Methods

Detailed protocols, Supplemental
MOLECULAR CHARACTERIZATION OF ISOLATED CTCs
The genetic material of single sorted cells was amplified using the adapter-linker PCR based on MseI digestion of the genome as previously described (17 ) , which is now commercialized as the Ampli1 TM whole genome amplification (WGA) kit by Silicon Biosystems. Chromosomal CNAs were analyzed by high-resolution arraybased comparative genome hybridization (aCGH) (16 ) . The same WGA products were used for a real-timebased assay to validate the amplification of the cyclin D1 (CCND1) 8 locus, and used to screen for mutations on exons 1, 9, and 20 of the phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) gene (see online Supplemental Table 5 ) and exons 5, 7, and 8 of the tumor protein p53 (TP53) gene by sequencing.
Results
SYSTEMATIC FLOW CYTOMETRY ANALYSIS OF CLINICAL
SAMPLES PROCESSED BY THE CellSearch SYSTEM
In a first step, we confirmed that under the used settings the MoFlo XDP device accurately isolated single cells from CellSearch cartridges and deposited them as single events for further analysis (see online Supplemental Fig. 1 pos cells, we first discriminated all events on the basis of the expression of CK and CD45 (Fig. 1) . We observed a very similar expression of these markers, resulting in a similar distribution of the events in the bivariate displays in 37/40 (92.5%) samples (see online Supplemental Fig. 2 and Supplemental Table 3 ). This enabled us to discriminate CK pos /CD45 neg events using an identical gate for all investigated samples. In the remaining 3 samples (samples 10, 22, and 40), high autofluorescence inter- The flow cytometry analyses allowed us to assess the extent of the undesired background present in CellSearch samples. We observed that the number of total events or DAPI pos events was not proportional to the number of CellSearch CTCs in the cartridges and varied considerably among samples ( Fig. 2A ; also see online Supplemental Fig. 4A and Supplemental Table 3 ). To evaluate the efficiency of the established flow cytometry protocol to detect CTCs in these samples, we compared the numbers of CTCs detected by flow cytometry (FC-CTCs) with the original CTC counts by the CellSearch system (CS-CTCs). Despite the variable background in the 36 successfully analyzed samples ( Fig. 2A ; also see online Supplemental Fig. 4A ) and the different storage times of the samples (see online Supplemental Table 1 and Supplemental Fig. 4B ), we observed a positive linear correlation (R 2 ϭ 0.9257) between the numbers of CTCs detected by the 2 techniques (Fig. 2B) . But it is of note that samples with longer storage times showed a larger spread from the optimal situation (100%) (see online Supplemental  Fig. 4B ). The median percentage of CS-CTCs detected by flow cytometry was 83.3% (range, 0%-300%; mean, 102%) (see online Supplemental Table 1 ). For only 1 sample, flow cytometry failed to detect CTCs, although 7 CS-CTCs were counted. On the other hand, we detected FC-CTCs at low numbers in only 2 of the 10 samples in which no CS-CTCs were detected (see online Supplemental Table 1 ). In total, 1163 CTCs defined as PE-CK pos /APC-CD45 neg /DAPI pos cells were detected in the set of clinical samples. From those detected CTCs, 883 were sorted from 27 CellSearch cartridges: 192 as single cells that were used for the present work and the rest as pools that were not further analyzed. We next aimed to evaluate if the single flowsorted FC-CTCs could be used for molecular analyses. For that we performed WGA and controlled the quality of the amplification product by a multiplex PCR (see online Supplemental 
CARCINOMA
After isolating single CTCs by their phenotype from CellSearch cartridges, we confirmed their malignant nature by aCGH. As proof of principle, we analyzed 2 cells randomly selected among those with Ն3 bands in the control multiplex PCR, from each of 13 cartridges of 12 patients (samples 34 and 38 were independent samples obtained from 1 patient). Of these 26 CTCs, 25 (96.2%) displayed CNAs typical for advanced breast carcinoma ( Fig. 3A ; also see online Supplemental Fig.  7 ), e.g., gains at chromosomes 1q, 8q, 11q, 16p,17q, 19, and 20q and deletions at chromosomes 8p, 11q, 16q, and 18q. One CTC showed an almost balanced profile, similar to those obtained from CD45 pos cells (Fig. 3A) . No significant differences in terms of quality and quantity of aberrations were observed in the genomic profiles of cells isolated from samples with Յ10 and Ͼ10 CS-CTCs (Fig. 3, B-D) . Interestingly, in our CTC collective, aCGH analysis revealed a frequent amplification (12/26 CTCs, 46.2%) of the oncogenic CCND1 gene locus (Fig. 4A) (18, 19 ) . Using the same 26 WGA products, we confirmed the gene amplification by performing a gene-specific genomic quantitative PCR (qPCR) assay in 11 of the 12 cases that displayed CCND1 amplification (Fig. 4B) . Furthermore, we used the same 26 WGA products to screen for mutations in Fig. 8 ). In the second cell of sample 23 (cell 23-2), which displayed an almost balanced aCGH profile, we did not detect any mutation in the exon 20 PIK3CA.
Discussion
CTCs detected by CellSearch have a strong prognostic impact in metastatic breast cancer patients (12 ) . Besides their enumeration, CTCs potentially provide access to the molecular characteristics of systemic cancer, and this information can be of value for diagnosis and therapy. In a very restricted way, further characterization of CTCs is already possible with the CellSearch system via the optional additional fluorescence channel, which allows assessment of 1 additional phenotypic marker, e.g., ERBB2 or EGFR expression (21, 22 ) . However, a more comprehensive molecular-genetic characterization is hampered because CellSearch was designed as a closed system and, more importantly, it does not provide pure CTCs. Instead, the cartridges contain a high background of up to 8000 hematopoietic cells that is not proportional to the number of Fig. 2A) . Consequently, after the release of the cellular content from a CellSearch cartridge, the rare CTCs must be further purified, which is technically challenging. Here, we show that flow sorting provides a fast, automatable, and effective solution for isolation and subsequent analysis of individual CTCs compared with other techniques also described, such as micromanipulation (23 ) . One other major advantage over microscope-based micromanipulation is that the standard fluorescence staining of the CellSearch system (PE-CK, APC-CD45, and DAPI) can be readily used for flow sorting. With one standardized flow-sorting protocol, we analyzed 90% of the clinical samples. Because we focused on the isolation and analysis of single CTCs, our protocol, which was designed for low SSCwidth values (Fig. 1) , was not applicable to 1 sample with a particularly high number of aggregates (sample 25). Because CTC aggregates are otherwise very interesting for further molecular analyses, aggregates should be successfully sorted without this discrimination criterion (low SSC-width).
CTCs (
The settings of our flow-sorting protocol could even successfully detect an FS-CTC in a sample that contained only 1 CS-CTC. Notably, and despite the considerable technical differences between CellSearch and flow cytometry, the number of CTCs isolated with our protocol showed a very good correlation with the number of expected CTCs as originally determined by the CellSearch system. Only 2 of the 10 tested negative cartridges showed very low numbers of presumably false-positive FC-CTCs, which is surprising considering the lack of morphological control in flow cytometry. This low number of presumably false-positive FCCTCs is in concordance with the low number of nonaberrant CTCs (3.8%) observed upon aCGH. During prolonged storage times of analyzed samples on the CellSearch cartridges, dye fluorescence intensities (DAPI, PE, APC) would be expected to de- Table comparing the log 2 ratio values obtained by aCGH for the CCND1 genomic region with the amplification probability score of CCND1 determined by RT-PCR. Values of the log 2 ratio of Ͼ1, corresponding to gains of the CCND1 locus superior to 2-fold, are highlighted in red; and probability scores above 0.95, defined as the threshold to be considered amplified, are highlighted in orange. ND, not done.
crease, which could substantially impact efficient identification of CTCs by flow cytometry. Although we did not perform a systematic analysis of this issue, we recommend an immediate further processing to avoid prolonged storage times, because we observed a weaker correlation between CS-CTC and FC-CTC numbers in samples stored for longer time periods (see online Supplemental Fig. 4B) .
A different flow-sorting protocol for isolation of CellSearch CTCs was very recently described by Swennenhuis et al (15 ) . For 10 tested clinical CellSearch samples of patients with lung cancer, the authors reported a markedly lower CTC detection rate (mean efficiency, 43% vs 102%; median efficiency, 41% vs 83%). This divergence in efficiency can be explained by several important differences between the 2 studies: (a) the FACS (fluorescence-activated cell sorting) instruments, (b) the gate settings, (c) the protocols used for transferring the cells from the cartridge without cell loss, and (d) potential differences in CK and CD45 expression on CTCs of breast and lung cancer, respectively.
Because we tested our approach in patients with metastatic breast cancer mainly with Ն5 CTCs in 7.5 mL peripheral blood, we anticipated all marker-positive cells to be genetically highly aberrant. We therefore checked the success rate of our work flow using aCGH (16 ) to interrogate CNAs in flow-sorted single CTCs. We successfully amplified 72.9% of the sorted cells via WGA, and 65.1% met the quality criteria (16 ) required for high-resolution aCGH analyses (see online Supplemental Fig. 5, A and B) . Interestingly, Peeters et al. (24 ) reported a similar WGA success rate, also using an adapter-linker PCR for spiked cancer cells isolated with the DEParray after CellSearch analysis.
Because longer cell fixation times and/or prolonged storage of cells might cause DNA fragmentation, which could be critical for WGAs based on digestion with a restriction enzyme and ligation of adapters (25, 26 ) , we checked whether we could detect quality differences in the WGA products. Our results obtained from the 192 cells analyzed did not reveal any significant decrease of WGA quality on cells fixed and/or stored for longer times (see online Supplemental Fig. 5 , C-E), possibly because of the special characteristics of the Veridex proprietary fixative reagent. However, if longer storage times become necessary, a systematic analysis to determine the longest possible storage period should be done.
The subsequent genetic characterization performed here proved that 96.2% of the sorted individual CTCs were in fact cancer cells. The genomic profiles obtained from CTCs show several aberrations typically observed in metastatic breast cancers (27 ) . Nevertheless, for 1 single marker-positive CTC, no significant chromosomal aberrations were observed and this cell also lacked the PIK3CA c.3140AϾT mutation on exon 20 found in another genetically aberrant single cell from the same patient. A similar observation in terms of balanced CGH profiles was made when micromanipulation was used to isolate CTCs with a CK pos / CD45 neg /DAPI pos phenotype, indicating that it is not a failure rate exclusive of the flow-sorting approach. Also, it is not clear at this point whether such balanced cells with a CTC phenotype are cancer cells. But according to our data, such cells are very rare in metastatic breast cancer. This is in contrast to the nonmetastatic situation in breast cancer, in which balanced profiles were observed in around 50% of CTCs (4 ) or disseminated tumor cells (DTCs) isolated from bone marrow (28 ) . Notably, both of the previous studies used low-resolution metaphase-based CGH and also a single CK staining. Whether this genotype pattern can be observed in CK pos /CD45 neg /DAPI pos CTCs of nonmetastatic breast cancer patients when array CGH is used needs to be determined. However, our genomic CTC data are generally in concordance with the genomic profiles of DTCs from bone marrow in the metastatic situation. Interestingly, in the CTCs investigated here we observed a high degree of genomic similarities also observed among DTCs in patients with metastasized breast cancer (29 ) . On the other hand, differences in CNAs between individual CTCs were clearly visible in all investigated cases. The power of our flow-sorting work flow for high-resolution profiling was exemplified by the direct identification of CCND1 as a frequently amplified gene in our study cohort. Cyclin D1, coded by the CCND1 gene, is a protein involved in cell cycle regulation, and amplification of its locus is also a long-recognized oncogenic factor in breast cancer (18, 19 ) . Using a novel qPCR assay for CCND1, we validated the precision of our array CGH approach. The reliability of this novel qPCR assay will have to be confirmed in a larger collective of cells/samples, but the results obtained so far suggest that it might have great utility for routine molecular diagnostics.
In summary, we describe a protocol that can be used for the systematic purification and subsequent genomic analysis of individual CTCs captured by CellSearch in clinical samples. The data obtained with our new work flow gave a first glimpse on the genomic makeup and heterogeneity of individual CTCs at high resolution in metastasized breast cancer patients. We believe that our approach will enhance and facilitate further molecular characterization of the rare CTCs, thus providing deeper insight into their biology and enabling their use as liquid biopsy samples. 
